Cynata Therapeutics Limited (51S) Financial Statements
Cynata Therapeutics Limited Financial Overview
Cynata Therapeutics Limited's market cap is currently $2.52M. The company's EPS TTM is $-0.04; its P/E ratio is -0.31; Cynata Therapeutics Limited is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.71M | $ 1.89M | $ 2.32M | $ 1.65M | $ 7.77M |
| Gross Profit | $ -260.31K | $ 1.89M | $ 2.32M | $ 1.37M | $ 7.49M |
| Operating Income | $ -9.68M | $ -8.12M | $ -8.81M | $ -16.54M | $ -6.90M |
| EBITDA | $ -9.42M | $ -9.33M | $ -9.95M | $ -15.65M | $ -6.00M |
| Net Income | $ -9.25M | $ -9.39M | $ -9.74M | $ -14.28M | $ -5.45M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 897.42K | $ 5.05M | $ 6.21M | $ 16.17M | $ 23.80M |
| Total Assets | $ 1.35M | $ 7.20M | $ 8.39M | $ 18.99M | $ 26.55M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -897.42K | $ -5.05M | $ -6.21M | $ -16.17M | $ -23.80M |
| Total Liabilities | $ 1.75M | $ 1.22M | $ 1.17M | $ 2.26M | $ 2.59M |
| Stockholders' Equity | $ -394.24K | $ 5.98M | $ 7.22M | $ 16.73M | $ 23.96M |
| Cash Flow | |||||
| Free Cash Flow | $ -6.74M | $ -8.77M | $ -9.96M | $ -14.28M | $ -3.30M |
| Operating Cash Flow | $ -6.74M | $ -8.72M | $ -9.96M | $ -14.28M | $ -3.30M |
| Investing Cash Flow | $ 0.00 | $ -50.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 2.58M | $ 7.61M | $ 0.00 | $ 6.72M | $ 210.12K |
Currency in AUD